At a glance
- Originator AstraZeneca
- Class Drug withdrawal therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 06 Apr 1995 Preclinical development for Neurological disorders in Sweden (Unknown route)